Table 4 Adverse events
From: Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study
Number (%) of patients | ||||||
|---|---|---|---|---|---|---|
Preferred term | AZD3199 | AZD3199 | AZD3199 | Formoterol | Total (n = 329) | |
200 μg od (n = 65) | 400 μg od (n = 69) | 800 μg od (n = 65) | 9 μg bid (n = 67) | Placebo (n = 63) | ||
Patients with any adverse event | 8 (12.3) | 21 (30.4) | 19 (29.2) | 18 (26.9) | 18 (28.6) | 84 (25.5) |
Nasopharyngitis | 1 (1.5) | 4 (5.8) | 3 (4.6) | 2 (3.0) | 3 (4.8) | 13 (4.0) |
Cough | 0 (0.0) | 4 (5.8) | 4 (6.2) | 2 (3.0) | 0 (0.0) | 10 (3.0) |
Chronic obstructive pulmonary disease | 1 (1.5) | 2 (2.9) | 2 (3.1) | 2 (3.0) | 2 (3.2) | 9 (2.7) |
Throat irritation | 1 (1.5) | 0 (0.0) | 1 (1.5) | 2 (3.0) | 1 (1.6) | 5 (1.5) |
Bronchitis | 0 (0.0) | 0 (0.0) | 2 (3.1) | 0 (0.0) | 2 (3.2) | 4 (1.2) |
Headache | 0 (0.0) | 2 (2.9) | 1 (1.5) | 1 (1.5) | 0 (0.0) | 4 (1.2) |
Product taste abnormal | 1 (1.5) | 0 (0.0) | 3 (4.6) | 0 (0.0) | 0 (0.0) | 4 (1.2) |